Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients
Нема приказа
Аутори
Ivanović, VesnaTodorović-Raković, N
Demajo, Miroslav
Nešković-Konstantinović, Zora
Nikolić-Vukosavljević, Dragica
Ivanišević-Milovanović, Olivera
Mitrovic, L
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinic...al attention.
Кључне речи:
TGF-beta(1) / plasma biomarkers / protease inhibitors / breast cancerИзвор:
Jugoslovenska Medicinska Biohemija, 2001, 20, 2, 81-87Колекције
Институција/група
VinčaTY - JOUR AU - Ivanović, Vesna AU - Todorović-Raković, N AU - Demajo, Miroslav AU - Nešković-Konstantinović, Zora AU - Nikolić-Vukosavljević, Dragica AU - Ivanišević-Milovanović, Olivera AU - Mitrovic, L PY - 2001 UR - https://vinar.vin.bg.ac.rs/handle/123456789/2438 AB - There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention. T2 - Jugoslovenska Medicinska Biohemija T1 - Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients VL - 20 IS - 2 SP - 81 EP - 87 UR - https://hdl.handle.net/21.15107/rcub_vinar_2438 ER -
@article{ author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica and Ivanišević-Milovanović, Olivera and Mitrovic, L", year = "2001", abstract = "There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.", journal = "Jugoslovenska Medicinska Biohemija", title = "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients", volume = "20", number = "2", pages = "81-87", url = "https://hdl.handle.net/21.15107/rcub_vinar_2438" }
Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Nikolić-Vukosavljević, D., Ivanišević-Milovanović, O.,& Mitrovic, L.. (2001). Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija, 20(2), 81-87. https://hdl.handle.net/21.15107/rcub_vinar_2438
Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D, Ivanišević-Milovanović O, Mitrovic L. Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija. 2001;20(2):81-87. https://hdl.handle.net/21.15107/rcub_vinar_2438 .
Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, Ivanišević-Milovanović, Olivera, Mitrovic, L, "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients" in Jugoslovenska Medicinska Biohemija, 20, no. 2 (2001):81-87, https://hdl.handle.net/21.15107/rcub_vinar_2438 .